NOVAVAX INC (NVAX)
US6700024010 - Common Stock
Shah Capital nominates two highly qualified independent director candidates for Novavax
Better Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs?
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Is there still too much risk surrounding this business?
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The 2024 presidential election is shaping up to be just as exciting and content...
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
These stocks could move in very different directions over the long run.
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress...
May 10th Options Now Available For Novavax (NVAX)
NVAX May 3rd Options Begin Trading
1 Beaten-Down Stock That's Still Not Worth Buying
For this biotech, a rebound seems far too unlikely.
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Bullish speculators could have their opportunity to blow up the bears with these short-squeeze stocks to buy.
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
Could these biotech companies still win in the vaccine market and beyond?
The Short List: 3 Meme Stock Battlegrounds to Keep on Your Radar
Explore the ups and downs of 3 meme stocks: Imperial Petroleum, Novavax and MicroCloud, as they navigate market challenges and speculation.
It’s Time! 3 Failing Biotech Stocks to Sell Right Now
The biotech industry offers investors unique investment opportunities but these three are biotechs to sell.
Exit Alert: 3 Overhyped Stocks With Weak Fundamentals
These are overhyped stocks to sell as they represent companies with weak fundamentals and prospects of cash burn.
Is Novavax a Buy Now?
The stock has dropped 98% over the past three years.
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Can the stock's recent rally continue?
Gritstone to cut 40% of staff due to funding delay, stock plunges 23% (NASDAQ:GRTS)
Gritstone bio (GRTS) shares plunged 23% in after-hours trading Thursday after the company disclosed it was slashing 40% of its workforce due to a funding delay. Read more here.
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will...
April 12th Options Now Available For Novavax (NVAX)
Why Is Advance Auto Parts (AAP) Stock Trending Today?
Advance Auto Parts stock is up on Wednesday even after posting EPS and revenue misses in its earnings report for the fourth quarter of 2023.
NVAX Stock Alert: 9 Reasons Why Novavax Investors Are So Disappointed Today
Novavax stock is falling hard on Wednesday as NVAX investors react to it missing estimates for Q4 and posting weak guidance for 2024!
Novavax stock falls as Q4 results disappoint (NASDAQ:NVAX)
Novavax (NVAX) stock falls 23% as Q4 results disappoint, with revenue down 19% YoY. Q4 net loss slips 2% YoY, but cash and equivalents drop by 58% YoY. Read more here.
Novavax GAAP EPS of -$1.44 misses by $0.99, revenue of $291M misses by $30.97M (NASDAQ:NVAX)
Novavax reports Q4 earnings miss with GAAP EPS of -$1.44 and revenue of $291M (-18.6% YoY).
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza...